Nutritional status changes in HIV-infected children receiving combined antiretroviral therapy including protease inhibitors.
Maintaining linear growth and weight gain in HIV-infected children is often difficult. Nutritional evaluation and support are recognised as important factors to improve their quality of life. Combination antiretroviral therapy including protease inhibitors (HAART) reduces HIV-viral load and improves survival, quality of life and nutritional status. Our study aimed to determine changes in nutrional status based on body weight, height and nutritional habits, of HIV-infected children receiving HAART. Possible side effects of lipid metabolism were also studied. Twenty five children, 13 treated with HAART (group B) were followed up for 12 months. We did not observe statistically significant differences in nutritional status over that time or between groups A and B. Inadequate energy intake was more common in patients with advanced HIV-disease. Hyperlipidemia was found in 70% of children receiving ritonavir and in approximately 50% of children receiving nelfinavir. We observed an important although not statistically significative modification in the height of those in group B.
Fiore
P
P
Dietetics Service, G. Gaslini Institute, Largo G. Gaslini, 5, 16147, Genoa, Italy. paolofiore@ospedale-gaslinis
Donelli
E
E
Boni
S
S
Pontali
E
E
Tramalloni
R
R
Bassetti
D
D
D000293:Adolescent; D019380:Anti-HIV Agents / Q000627:therapeutic use; D001827:Body Height / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D050356:Lipid Metabolism; D008137:Longitudinal Studies; D008297:Male; D009752:Nutritional Status
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors